CNS SpectrumsFebruary 19, 2025M. Koummati, J. Vrublevska, M. de Hert et al.
Background It has been reported that abnormal experiences could be common in the general “healthy” population, with the vast majority of individuals never proceeding to manifest a frank mental disorder. Aims This study aimed to quantify subthreshold psychiatric symptoms in the general population. Methods The protocol included clinicodemographic data and a mental symptoms questionnaire, and...
Ketamine is an N-methyl-D-aspartate antagonist which has been a major focus of research recently and is being used as a putative treatment for depression and other neuropsychiatric disorders. Along with psychedelic agents, ketamine (and the derivative esketamine) are not only the main harbingers of potentially new classes of psychiatric drugs but may also share some common features (Marguilho...
As we head into the (Northern Hemisphere) spring, the Journal publishes another set of papers which illustrate the robust health of the science of psychopharmacology. Once again, papers mostly focus on psychedelic drugs and related topics reflecting the zeitgeist (Young, 2022). de Wit et al. (2022) explore translational challenges and opportunities between clinical research and laboratory...
The 21st century has seen a dramatic flow and ebb in the fortunes of clinical psychopharmacology particularly with regard to antidepressants. For about 20 years, perhaps from about 1985 onwards, the tide flowed in with many ‘new’ drugs being made available to clinicians. In mood and psychotic disorders, these were essentially incremental advances from old drugs such as amitriptyline and...